Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients

Rainel Sánchez-de la Rosa; Eliazar Sabater; Miguel Angel Casado; Rafael Arroyo

doi:10.3111/13696998.2012.654868

Cost-effectiveness analysis of disease modifiying drugs (interferons and glatiramer acetate) as first line treatments in remitting-relapsing multiple sclerosis patients

Journal of Medical Economics ◽

10.3111/13696998.2012.654868 ◽

2012 ◽

Vol 15 (3) ◽

pp. 424-433 ◽

Cited By ~ 15

Author(s):

Rainel Sánchez-de la Rosa ◽

Eliazar Sabater ◽

Miguel Angel Casado ◽

Rafael Arroyo

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Multiple Sclerosis Patients ◽

Relapsing Multiple Sclerosis

Download Full-text

PND28 Cost-Effectiveness Analysis of Interferons and Glatiramer Acetate as First Line Treatments in Remitting – Relapsing Multiple Sclerosis Spanish Patients

Value in Health ◽

10.1016/j.jval.2011.08.494 ◽

2011 ◽

Vol 14 (7) ◽

pp. A322

Author(s):

R. Sánchez-de la Rosa ◽

E. Sabater ◽

M.A. Casado

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Relapsing Multiple Sclerosis

Download Full-text

PND8 COST-EFFECTIVENESS ANALYSIS OF REBIF IN FIRST-LINE RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY

Value in Health ◽

10.1016/s1098-3015(10)66969-0 ◽

2008 ◽

Vol 11 (6) ◽

pp. A602

Author(s):

MJ Nuijten ◽

T Mittendorf ◽

A Jäcker ◽

U Osowski

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis

Journal of Medical Economics ◽

10.3111/200104207219 ◽

2001 ◽

Vol 4 (1-4) ◽

pp. 207-219 ◽

Cited By ~ 9

Author(s):

Uday Bose ◽

David Ladkani ◽

Anita Burrell ◽

Mohammad Sharief

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis

Journal of Medical Economics ◽

10.1080/13696998.2017.1355310 ◽

2017 ◽

Vol 20 (10) ◽

pp. 1056-1065 ◽

Cited By ~ 8

Author(s):

Hongbo Yang ◽

Emilie Duchesneau ◽

Rebekah Foster ◽

Annie Guerin ◽

Esprit Ma ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Interferon Beta ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Multiple Sclerosis

Download Full-text

PND65 - COST-EFFECTIVENESS ANALYSIS OF DRUGS USED FOR THE TREATMENT OF HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL

Value in Health ◽

10.1016/j.jval.2018.09.2031 ◽

2018 ◽

Vol 21 ◽

pp. S340

Author(s):

N Silverio ◽

A Fonseca

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

Highly Active ◽

Effectiveness Analysis ◽

Relapsing Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain

Value in Health ◽

10.1016/j.jval.2017.08.1948 ◽

2017 ◽

Vol 20 (9) ◽

pp. A723

Author(s):

L Ruiz ◽

H Toro-Diaz ◽

C Cele ◽

L Hernandez ◽

A Harrington

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis ◽

Disease Modifying Therapies ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States

Journal of Medical Economics ◽

10.3111/13696998.2016.1157080 ◽

2016 ◽

Vol 19 (7) ◽

pp. 684-695 ◽

Cited By ~ 14

Author(s):

Luis Hernandez ◽

Shien Guo ◽

Elizabeth Kinter ◽

Monica Fay

Keyword(s):

United States ◽

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

The United States ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

PND13 A COST-EFFECTIVENESS ANALYSIS OF NATALIZUMAB VS. INTERFERON-BETA AND GLATIRAMER ACETATE IN PATIENTS WITH ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS CURRENTLY FAILING ON EXISTING THERAPY

Value in Health ◽

10.1016/s1098-3015(10)70446-0 ◽

2008 ◽

Vol 11 (3) ◽

pp. A140 ◽

Cited By ~ 1

Author(s):

R Gani ◽

ER Samuels ◽

S Hughes ◽

G Giovanonni

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Cost Effectiveness Analysis ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Remitting Multiple Sclerosis ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada

PharmacoEconomics ◽

10.1007/s40273-021-01022-9 ◽

2021 ◽

Author(s):

Yong-Jin Kim ◽

Mark Oremus ◽

Helen H. Chen ◽

Thomas McFarlane ◽

Danielle Fearon ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Egfr Mutation ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Effectiveness Analysis

Download Full-text

P-2 First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: A cost-effectiveness analysis

Annals of Oncology ◽

10.1016/j.annonc.2021.05.057 ◽

2021 ◽

Vol 32 ◽

pp. S97

Author(s):

S. Chan ◽

C. Chiang ◽

S. Lee ◽

H. Choi

Keyword(s):

Hepatocellular Carcinoma ◽

Cost Effectiveness ◽

Cost Effectiveness Analysis ◽

First Line ◽

Effectiveness Analysis

Download Full-text